Biogen Inc. (SNSE:BIIB)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of CLP 19.33 trillion. The enterprise value is 23.01 trillion.

Market Cap	19.33T
Enterprise Value	23.01T

Important Dates

The next estimated earnings date is Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.61M
Shares Outstanding	n/a
Shares Change (YoY)	+0.31%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.23M

Valuation Ratios

The trailing PE ratio is 13.56 and the forward PE ratio is 8.96.

PE Ratio	13.56
Forward PE	8.96
PS Ratio	2.08
PB Ratio	1.18
P/TBV Ratio	12.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.18, with an EV/FCF ratio of 12.49.

EV / Earnings	16.14
EV / Sales	2.40
EV / EBITDA	7.18
EV / EBIT	9.68
EV / FCF	12.49

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.37.

Current Ratio	2.50
Quick Ratio	1.52
Debt / Equity	0.37
Debt / EBITDA	1.97
Debt / FCF	3.33
Interest Coverage	9.82

Financial Efficiency

Return on equity (ROE) is 9.13% and return on invested capital (ROIC) is 6.62%.

Return on Equity (ROE)	9.13%
Return on Assets (ROA)	5.62%
Return on Invested Capital (ROIC)	6.62%
Return on Capital Employed (ROCE)	9.85%
Revenue Per Employee	1.22B
Profits Per Employee	187.44M
Employee Count	7,605
Asset Turnover	0.36
Inventory Turnover	1.02

Taxes

In the past 12 months, Biogen has paid 248.86 billion in taxes.

Income Tax	248.86B
Effective Tax Rate	14.86%

Stock Price Statistics

The stock price has decreased by -46.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-46.84%
50-Day Moving Average	130.24
200-Day Moving Average	200.82
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.44

Income Statement

In the last 12 months, Biogen had revenue of CLP 9.31 trillion and earned 1.43 trillion in profits. Earnings per share was 9,736.61.

Revenue	9.31T
Gross Profit	7.04T
Operating Income	2.31T
Pretax Income	1.67T
Net Income	1.43T
EBITDA	3.00T
EBIT	2.31T
Earnings Per Share (EPS)	9,736.61

Balance Sheet

The company has 2.57 trillion in cash and 6.14 trillion in debt, giving a net cash position of -3,572.55 billion.

Cash & Cash Equivalents	2.57T
Total Debt	6.14T
Net Cash	-3,572.55B
Net Cash Per Share	n/a
Equity (Book Value)	16.42T
Book Value Per Share	112,031.23
Working Capital	4.46T

Cash Flow

In the last 12 months, operating cash flow was 1.97 trillion and capital expenditures -128.53 billion, giving a free cash flow of 1.84 trillion.

Operating Cash Flow	1.97T
Capital Expenditures	-128.53B
Free Cash Flow	1.84T
FCF Per Share	n/a

Margins

Gross margin is 75.58%, with operating and profit margins of 24.79% and 15.31%.

Gross Margin	75.58%
Operating Margin	24.79%
Pretax Margin	17.98%
Profit Margin	15.31%
EBITDA Margin	32.23%
EBIT Margin	24.79%
FCF Margin	19.79%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.31%
Shareholder Yield	n/a
Earnings Yield	7.37%
FCF Yield	9.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3.16 and a Piotroski F-Score of 6.

Altman Z-Score	3.16
Piotroski F-Score	6